Bioqual, Inc. (BIOQ)

Market Cap	27.40M -29.1%
Revenue (ttm)	39.95M -18.3%
Net Income	-4.17M
EPS	-4.66
Shares Out	894.42K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	32.90
Previous Close	33.00
Day's Range	30.64 - 32.90
52-Week Range	30.64 - 38.51
Beta	-0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 23, 2026

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1981
• Employees: 113
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOQ

Financial Performance

In fiscal year 2026, Bioqual's revenue was $39.95 million, a decrease of -18.25% compared to the previous year's $48.87 million. Losses were -$4.17 million, 297.7% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error